Cancer Epidemiology

项目总结 莫菲特癌症中心(MCC)癌症流行病学(CE)计划的目标是为减少 通过研究确定包括病因学在内的整个癌症连续体的风险因素， 进展和结果，并将这些知识转化为成功的预防和早期发现 干预措施。技术进步带来的信息的快速增长提供了机会 阐明癌症发病的根本原因。疾病集合的复杂性被称为 癌症需要一种强有力的方法和对广泛的生物标志物的考虑。身份的鉴定 改变癌症易感性的标记物允许开发和测试临床癌症预防 战略。为了实现其目标，CE计划被组织为三个具体目标，重点是1) 癌症风险和结果的获得性生物标记物的鉴定和检测，2)遗传病的检查 易感标志物及其与癌症风险和预后的关联；以及3)发现和检测 预防和早期发现癌症的有希望的方法。行政长官调查如何 生物标志物，其中一些是可修改的，影响疾病的发生、进展和结局，以及这些 生物标记物可以被引入临床和公共卫生领域，以产生翻译影响。工作是 与健康结果和行为方案(HOB)的同事密切合作进行，世卫组织 寻求更好地了解影响可变生物标志物的行为，并修改这些行为以减少 癌症风险和促进早期发现。因此，行政长官的具体目标与行政长官的目标相辅相成 HOB，两个计划的成员之间有相当大的协同效应。 该项目由来自六个学术部门的24名成员组成。同行评审资金为670万美元 每年的总成本，其中来自NCI的资金部分为580万美元，占 该项目的同行评审资金。项目成员发表了635篇与癌症相关的学术文章 包括58篇影响较大的期刊(影响因子为10)。总共，174份(27%)的出版物代表内部 方案协作，147(23%)代表方案间协作，292(46%)反映 与NCI指定的其他癌症中心的机构间合作。事实上，现任行政长官成员 拥有37个跨机构协作奖项。由项目成员领导的科学调查帮助了 风险因素的高级知识，包括甲基化标志物、人乳头状瘤和其他病毒， 许多癌症的microRNA特征和基因多态，这些都是导致癌症的主要因素 MCC集水区以及其他癌症的死亡率和发病率。CE计划成员也是 积极通过开发更好的疫苗、植物化学预防制剂来转化他们的工作，以及 自动化数字成像，以影响临床和公共卫生实践。

PROJECT SUMMARY The goal of the Moffitt Cancer Center (MCC) Cancer Epidemiology (CE) Program is to contribute to a reduction in the cancer burden through research to identify risk factors across the cancer continuum comprising etiology, progression, and outcome, and the translation of that knowledge into successful prevention and early detection interventions. Rapid increases in information enabled by advances in technology have provided the opportunity to clarify underlying causes of cancer pathogenesis. The complexity of the collection of diseases known as cancer requires a robust approach and consideration for a broad array of biomarkers. The identification of markers that alter susceptibility to cancer allows for the development and testing of clinical cancer prevention strategies. To achieve its goal, the CE Program is organized into three specific aims focused on 1) identification and testing of acquired biomarkers of cancer risk and outcome, 2) examination of inherited susceptibility markers and associations with cancer risk and outcome, and 3) discovery and testing of promising approaches for the prevention and early detection of cancer. CE members investigate how biomarkers, some of which are modifiable, impact disease onset, progression, and outcome and whether these biomarkers can be brought forward into the clinical and public health realms for translational impact. Work is conducted in close collaboration with colleagues in the Health Outcomes and Behavior (HOB) Program, who seek to better understand behaviors that affect mutable biomarkers and modify those behaviors to decrease cancer risk and promote early detection. Thus, the specific aims of CE are highly complementary to those of HOB, and there is considerable synergy between members of both programs. The program comprises 24 members from six academic departments. Peer-reviewed funding is $6.7M in annual total costs, and the portion of this funding derived from NCI is $5.8M, representing 86% of the program's peer-reviewed funding. Program members have published 635 cancer-relevant scholarly articles including 58 in high impact journals (impact factor >10). In total, 174 (27%) of all publications represent intra- programmatic collaborations, 147 (23%) represent inter-programmatic collaborations, and 292 (46%) reflect inter-institutional collaborations with other NCI-designated Cancer Centers. Indeed, CE members currently have 37 inter-institutional collaborative awards. Scientific investigations led by program members have helped advance knowledge of risk factors, including methylation markers, human papilloma and other viruses, microRNA signatures, and genetic polymorphisms, for numerous cancers that are the major contributors to mortality and morbidity in the MCC catchment area, and for other cancers. CE Program members also are active in translating their work through developing better vaccines, botanical chemopreventive agents, and automated digital imaging to impact clinical and public health practice.